The global market for hypercalcemia treatment is poised for substantial growth, with a valuation of USD 18.07 billion in 2023. Exhibiting a remarkable CAGR of 11.8% over the forecast period (2023–2033), the market is projected to reach an impressive valuation of USD 55.07 billion by 2033.
Key Growth Factors:
- Rising Incidence of Hypercalcemia
The increasing prevalence of hypercalcemia-related conditions, such as malignancy-associated hypercalcemia and parathyroid disorders, is a significant driver for market growth. - Advancements in Treatment Modalities
Innovations in therapeutic options, including calcimimetic agents, bisphosphonates, and biologics, are driving the adoption of effective hypercalcemia management strategies. - Growing Awareness and Diagnostics
Improved awareness of hypercalcemia’s complications and advancements in diagnostic technologies are enabling early detection and treatment, contributing to market expansion. - Increasing Healthcare Investments
Rising healthcare expenditures globally and an aging population are fueling demand for hypercalcemia treatment options, particularly in developed and emerging markets.
Get Full Report Now – https://www.futuremarketinsights.com/reports/hypercalcemia-treatment-market
Regional Insights:
North America remains the dominant market due to well-established healthcare systems and high awareness. Meanwhile, the Asia-Pacific region is anticipated to witness the fastest growth, fueled by expanding healthcare access and increasing disease burden.
Future Outlook:
The hypercalcemia treatment market is expected to flourish with continued advancements in targeted therapies, personalized medicine approaches, and increasing focus on improving patient outcomes.
Competitive Landscape
Companies indulged in developing hypercalcemia drugs and treatment therapies are actively seeking to strengthen their position through approval, and agreements with established healthcare institutes. Also, collaborations, mergers & acquisition partnerships with regional players can accelerate their strategy to capture a significant share of the emerging markets.
The emergence of many biotech firms for conducting research and development on hypercalcemia diagnosis and therapy also could be a factor for further market growth. They are developing medicines and APIs manufactured in individual and combination doses for the treatment of hypercalcemia associated with thyroid tumors and other illnesses.
Key Developments
- In April 2021, Novartis AG announced a collaboration with Artios Pharma. This collaboration was made to improve both companies’ discovery platforms, leverage their knowledge, and improve the potential of radio ligand therapies for treating cancers of both companies.
- In June 2021, Bayer AG and Aurexel Life Sciences published their collaborative article reports where they announced promising results with the use of combination therapy of radium-223 and bortezomib. It was used for treating multiple myeloma bone disease.
- In September 2021, Sunovian Pharmaceuticals announced a joint development and collaboration with Otsuka Pharmaceutical Co. This collaboration was made as an effort to improve the research and development activities to improve their production of novel drug compounds.
- In January 2021, Bayer AG announced the USA FDA priority review for their New Drug Application for Finerenone drug used to treat patients with chronic kidney disease and associated Type 2 diabetes.
Key Companies Profiled
- Amgen Inc.
- Pfizer Inc.
- Mylan N. V.
- Sunovion
- Procter And Gamble
- Apotex Corporation
- Genentech, Inc.
- Novartis AG
- Bayer AG
- Hoffmann La Roche
- Atnahs Pharma
- Cipla Inc.
- Sun Pharmaceuticals Industries Ltd
- Dr. Reddy’s Laboratories
- Aurobindo Pharma Limited
Key Market Segments Covered In Hypercalcemia Treatment Industry Research
By Product:
- Bisphosphonates
- Clodronate
- Ibandronate
- Pamidronate
- Zoledronic Acid
- Calcitonin
- Glucocorticoids
- Denosumab
- Calcimimetics
By Distribution Channel:
- Hospitals
- Clinics
- Independent Pharmacy & Drug Stores
By Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- The Middle East and Africa (MEA)
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube